Disc Medicine (IRON) Common Equity (2020 - 2026)

Disc Medicine (IRON) has 7 years of Common Equity data on file, last reported at $688.4 million in Q1 2026.

• Quarterly Common Equity rose 4.25% year-over-year to $688.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $688.4 million (up 4.25% YoY) and the FY2025 annual result came in at $739.8 million, up 66.78% from the prior year.
• Common Equity eased to $688.4 million in Q1 2026 per IRON's latest filing, from $739.8 million in the prior quarter.
• Across five years, Common Equity topped out at $739.8 million in Q4 2025 and bottomed at -$98.5 million in Q3 2022.
• The 5-year median for Common Equity is $371.2 million (2023), against an average of $367.3 million.
• The widest annual swing landed in 2022, when Common Equity slumped 169.95%; it then soared 548.44% in 2023.
• Tracing IRON's Common Equity over 5 years: stood at $176.6 million in 2022, then surged by 95.43% to $345.1 million in 2023, then increased by 28.53% to $443.6 million in 2024, then soared by 66.78% to $739.8 million in 2025, then slipped by 6.95% to $688.4 million in 2026.
• Per Business Quant, the three latest IRON Common Equity figures stand at $688.4 million (Q1 2026), $739.8 million (Q4 2025), and $573.4 million (Q3 2025).

Peer Comparison